Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (RHHVF)
OTHER OTC:RHHVF
RHHVF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$269.80 - $354.19
Previous CloseN/A
Volume301.00
Average Volume (3M)16.04K
Market Cap
$262.99B
Enterprise Value$232.87B
Total Cash (Recent Filing)$12.03B
Total Debt (Recent Filing)$34.63B
Price to Earnings (P/E)24.1
Beta0.37
Next Earnings
Jan 29, 2026EPS Estimate
10.71Last Dividend Ex-Date
Mar 28, 2025Dividend Yield3.32%
Share Statistics
EPS (TTM)13.84
Shares Outstanding702,562,700
10 Day Avg. Volume17,710
30 Day Avg. Volume16,040
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)6.41
Price to Sales (P/S)3.26
P/FCF Ratio13.50
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue5.00
Enterprise Value/Gross Profit6.80
Enterprise Value/Ebitda18.62
Forecast
1Y Price Target
$332.67Price Target Upside0.67% Upside
Rating ConsensusHold
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Cost ManagementH1'25 group operating profit came in 2% ahead, supported by sales and greater cost discipline.
Earnings PerformanceQ2'25 sales beat consensus by 1%, driven by a stronger Pharmaceuticals (2% beat).
Pharmaceutical SalesKey drivers of the Pharma sales beat include Hemlibra, Xolair, and Actemra, which were ahead by 12%, 19%, and 14% respectively.
Bears Say
Financial ValuationValuation looks demanding given softer earnings growth compared to peers, leading to a downgrade to relative Underweight.
Market CompetitionLonger-term growth appears challenged due to potential branded and biosimilar competition, which is likely to increase.
Regulatory ChallengesRecent safety and regulatory setbacks for key new launches contribute to downside risk for earnings expectations.
Roche Holding AG News
RHHVF FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was $269.80 and its highest was $354.19 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $262.99B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jan 29, 2026 which is in 133 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 24, 2025. The company reported $13.841 earnings per share for the quarter, beating the consensus estimate of $13.454 by $0.387.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of $10.972 which represents an annual dividend yield of 3.32%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 10.71.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of $13.841 in its last earnings report, beating expectations of $13.454. Following the earnings report the stock price went up 1.338%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in RHHVF
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
RHHVF Company Deck
RHHVF Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted strong growth in pharmaceutical sales and robust pipeline development, particularly in oncology and neurology. However, challenges in the Diagnostics segment due to China's pricing reforms and mixed clinical trial results tempered the positive outlook. Additionally, regulatory setbacks and geopolitical uncertainties added caution.View all RHHVF earnings summariesRHHVF Stock 12 Month Forecast
Average Price Target
$332.67
▲(0.67% Upside)
Technical Analysis
Ownership Overview
―
Insiders
10.38% Mutual Funds
0.05% Other Institutional Investors
76.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---